A Phase I/II Gene Therapy Trial for X-CGD With a SIN Gammaretroviral Vector
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 5
- 试验地点
- 2
- 主要终点
- Transduction rate of granulocyte colony-stimulating factor (G-CSF) mobilized peripheral CD34+ cells from CGD patients with a SIN gamma retroviral vector
研究概览
简要总结
X-linked chronic granulomatous disease (X-CGD) is a rare inherited immune defect, which is caused by the inability of phagocytic cells to produce reactive oxygen species due to a defect in the gp91phox subunit of the NADPH oxidase complex. X-CGD patients suffer from recurrent and life-threatening infections and severe hyperinflammatory complications.
The only curative treatment for X-CGD is allogenic hematopoietic stem cell transplantation, but this procedure implies severe risks and many patients lack an appropriate donor. Therefore alternative curative approaches are urgently needed. In this study, patients will be treated with gene-corrected autologous CD34+ cells, using a SIN gammaretroviral vector for ex-vivo gene-therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Verified diagnosis of the X-linked form of chronic granulomatous disease, with loss of gp91phox expression (Western Blot). Evidence of less than 5% of normal oxidase production in circulating neutrophil granulocytes as measured by dihydrorhodamine- (DHR-) and nitro blue tetrazolium- (NBT-) assay
- •History of severe chronic infections with life-threatening course or severe steroid- sensitive or steroid insensitive granulomatous disease, with necessity of inpatient treatment, without sustained improvement even under maximum conservative treatment measures
- •No Human Leukocyte Antigen (HLA) identical (10/10 match) sibling- or unrelated donor, or contraindications for allogenic stem cell transplantation in presence of a suitable donor. The lack of an HLA-identical (10/10 match) sibling- or unrelated donor has to be confirmed by an unsuccessful search in national and international donor registers for at leat 3 months
- •Normal organ-function: glomerular filtration rate (GFR) ≥ 60ml/min., Bilirubin ≤ 1.5-fold upper reference-level, normal parameters for liver enzymes and clotting (TPZ 75-100%, partial thromboplastin time (PTT) 30-38sec, Fibrinogen 200-400mg/dl), Leukocytes > 3 x 10^9/l, Granulocytes > 1.5 x 10^9/l, Thrombocytes >100 x 10^9/l
- •Contraception from start of G-CSF application until 1 year after retransfusion of the gene-corrected cells
- •No interferon-gamma injection within two weeks prior to hematopoietic stem cell mobilization
- •Karnofsky-Index > 70%
- •Signed informed consent
排除标准
- •Patients with non-controlled acute infections
- •Severe cardiac or pulmonary malfunctions: ejection fraction < 60%, valvular heart disease > II°, arrhythmia requiring therapy, forced expiratory volume at one second/vital capacity (FEV1/VC) < 75% , diffusion capacity of lung for carbon monoxide (DLCO) <60%
- •Bilirubin > 1.5-fold upper reference-level
- •HIV-, Hepatitis B- or C - infection
- •Contraindications for G-CSF administration, as autoimmune vasculitis.
- •Contraindications for stem cell apheresis, as low hemoglobin < 8g/dl, cardiovascular instability or severe coagulopathy
- •Pregnancy or breast-feeding
- •Drug- or alcohol-abuse
- •Lack of search for an unrelated donor
- •Patients with a HLA 9/10 mismatched unrelated donor (MMUD) will be excluded, if a thorough risk-benefit analysis favors allogenic hematopoietic stem cell transplantation (HSCT)
结局指标
主要结局
Transduction rate of granulocyte colony-stimulating factor (G-CSF) mobilized peripheral CD34+ cells from CGD patients with a SIN gamma retroviral vector
时间窗: 1 week
Engraftment rate of the transduced CD34+ cells in the patients
时间窗: 5 years
Long-term expression of the transgene (rate of gp91phox positive cells) in circulating cells in the peripheral blood
时间窗: 5 years
Functional reconstitution of the NADPH oxidase in circulating cells of the peripheral blood (% DHR positive cells)
时间窗: 5 years
Frequency and severity of unexpected toxic adverse events during and after infusion of the genetically modified CD34+ cells
时间窗: 5 years
次要结局
- Frequency of infections as indicator for the clinical benefit for the patients(5 years)
- Proliferation rate of CD34+ cells in ex-vivo culture under serum-free conditions(up to 3 weeks)
- Differentiation rate of CD34+ cells (as measured by flow cytometry) in ex-vivo culture under serum-free conditions(up to 3 weeks)
- Transduction rate of CD34+ cells in ex-vivo culture under serum-free conditions(up to 12 weeks)
研究者
Hubert Serve, Prof., MD
Head of Medical Department II
Johann Wolfgang Goethe University Hospital